End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 NZD | 0.00% | -2.17% | -18.55% |
06-26 | New Zealand Shares Jump on Manufacturing, Tech Services Gains; EROAD Secures Three-Year Fleet Contract | MT |
06-26 | Vital Healthcare Contracts NZ$87 Million of Non-Core Asset Sales Since April | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.55% | 737M | D+ | ||
+15.61% | 62.33B | A- | ||
-1.01% | 13.79B | A | ||
+11.71% | 8.46B | B | ||
-3.48% | 6.24B | B- | ||
+12.15% | 3.63B | C- | ||
+7.92% | 3.57B | C+ | ||
+21.27% | 2.94B | C- | ||
-11.00% | 2.89B | B+ | ||
-12.22% | 2.59B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VHP Stock
- Ratings Vital Healthcare Property Trust